AstraZeneca to Acquire Respiratory Portfolio from Takeda for $575M

Takeda Pharmaceutical Company Limited TKPYY today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca AZN. In 2014 Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic. This divestiture will allow Takeda to work on becoming best-in-class in these therapeutic areas, while maintaining continuity of care for patients. "Patients are Takeda's primary focus and we are committed to working closely with AstraZeneca to ensure a smooth transition," said Christophe Weber, Chief Executive Officer, Takeda Pharmaceutical Company Limited. "AstraZeneca has extensive experience in respiratory care and will be able to prioritize getting these important medicines to the patients See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsAsset SalesM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!